药物相关性颌骨坏死的研究进展  

The research in medication-related osteonecrosis of the jaw

作　　者：沈亚俊 关键[2] 葛成[3] 

机构地区：[1]佳木斯大学附属口腔医院,黑龙江154004 [2]佳木斯大学附属口腔医院口腔颌面外科,黑龙江154004 [3]解放军307医院口腔科,北京100071

出　　处：《中华老年口腔医学杂志》2016年第4期242-247,共6页Chinese Journal of Geriatric Dentistry

基　　金：北京市自然科学基金资助项目(项目编号:7152110)

摘　　要：随着双膦酸盐的广泛应用,由其导致的颌骨坏死的副作用不断被报道。通过近几年的研究发现,抗骨吸收药物或抗血管生成药物均能导致同样的颌骨坏死发生,随即药物性相关性颌骨坏死的概念被报道,引起了界内的广泛关注。但究其具体的发病机制,目前仍无明确定论,而针对该病的诊断和治疗也未有统一认识,本文就目前关于药物性颌骨坏死的最新研究进展作一综述。With the wide application of bisphosponate, osteonecrosis of jaw caused by bisphosphonate has been reported constantly. In recent years, some studies found that antiresorptive or antiangiogenic medications could also lead to osteonecrosis of jaw, the concept of Medication-related Osteonecrosis of the Jaw has been reported and attracted broad attention. But the pathophysiology of the disease has not been clear so far, and the diagnosis and treatment of the disease also has not been fully elucidated. So the literature review is aimed to summarize the latest research progress in Medication-related Osteonecrosis of the Jaw.

关 键 词：双膦酸盐 颌骨 骨坏死 机制 

分 类 号：R782.2[医药卫生—口腔医学]